Anti-Mullerian Hormone

Following the Dobbs v. Jackson Women's Health Organization decision, rates of vasectomy and tubal sterilization rose, according to data presented at the American Society for Reproductive Medicine Scientific Congress & Expo.

NEW ORLEANS — Women with lower levels of anti-Müllerian hormone may take longer to become pregnant naturally, without use of assisted reproductive technologies, than their same-age peers with higher levels, according to a speaker.

A review of websites selling direct-to-consumer anti-Müllerian hormone tests found that most of them made false claims, potentially misleading consumers into believing the tests can predict chances of conception and age of menopause.

Most websites selling direct-to-consumer anti-Müllerian hormone tests had false and misleading claims, possibly leading consumers to believing the tests predict fertility potential and age of menopause, according to researchers.

Women with lower levels of anti-Müllerian hormone may experience greater bone loss during menopause transition, according to study findings published in the Journal of Bone and Mineral Research.

Women with germline BRCA mutations have lower levels of anti-Müllerian hormone than women without these mutations, according to results of a meta-analysis published in Journal of Clinical Oncology.

Neuroendocrine, reproductive and metabolic dysfunctions associated with polycystic ovary syndrome are transmitted in mice exposed prenatally to anti-Müllerian hormone for at least three generations, new data show.

Chemotherapy is known to increase a woman’s risk for infertility, and women with BRCA mutations have lower ovarian reserves and higher risk for developing breast cancer.

Levels of anti-Müllerian hormone and the soluble anti-Müllerian hormone receptor 2 could indicate the severity of glucose metabolism impairment associated with remaining ovarian function among women with polycystic ovary syndrome.